BAGHDAD: Iraq began coronavirus vaccinations on Tuesday, inoculating medical staff hours after a military plane brought in 50,000 Sinopharm jabs donated by China.
The campaign was launched as Iraq battles a second wave of COVID-19 infections, with more than 4,600 new cases a day, and ahead of a three-day visit by Pope Francis from Friday.
“The vaccines arrived overnight and we immediately distributed them to health centers and began the vaccinations,” Health Minister Hassan Al-Tamimi said at Baghdad’s Medical City hospital compound.
“We will be carrying out more vaccinations tomorrow in the provinces and remote areas.”
Aside from health workers, security forces and the elderly will be first to receive the free-of-charge vaccine, his ministry said on a citizens’ registration platform which, however, was not functional.
The public health infrastructure in Iraq, a country of 40 million, has been severely worn down by decades of war, under-investment and corruption.
The Health Ministry has said it agreed with the Chinese ambassador in Baghdad to purchase another 2 million Sinopharm doses, but provided no details on the cost or the timing. Iraqi authorities said in January they had approved three vaccines for use, but there have been repeated delays and contradictory statements from health authorities.
The ministry said it was expecting to receive a total of 16 million jabs through the global Covax scheme, through which wealthy nations are meant to allocate vaccines for poorer countries.

That figure appeared to be based on Covax’s pledge that, subject to funding, it could help poorer countries vaccinate 20 percent of their populations — or 8 million people in Iraq.
The ministry has also said it would receive 3 million AstraZeneca jabs, but the World Health Organization has only approved the distribution of 2 million of those doses to Iraq through Covax.
The ministry also says it has secured funding from the World Bank for 1.5 million jabs from Pfizer/BioNTech, but the deal requires a parliamentary vote which has yet to be held.
Sinopharm affiliate the Wuhan Institute of Biological Products says its vaccine has an efficacy rate of 72.51 percent, behind rival jabs by Pfizer/BioNTech and Moderna, which have 95 percent and 94.5 percent rates respectively.